Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | December 29, 2011 | December 21, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Director | March 31, 2025 | April 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 29, 2011 · Filed December 21, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 49,432 |
Reported balance
After 2011-12-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2011-12-29 · Gift · Disposed 24,982 · Balance 49,432 F1: Reflects the transfer of 111,161 Abbott common shares that was exempt from Section 16. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the transfer of 111,161 Abbott common shares that was exempt from Section 16.
AbbVie Inc.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 386,479 |
Reported balance
After 2025-03-31 transaction · row 1
1 source rowRow 1 · 2025-03-31 · Gift · Disposed 2,450 · Balance 386,479 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2021 Filed Dec 10, 2021 17:02 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 174,100 | $61.36 | $10,682,776.00 |
DisclosureSEC source: 0001179110-21-010830 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 20:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right To Buy) · Derivative | 170,113 | $54.86 Strike: $0.00 | $9,332,399.18 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · derivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,113 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 20:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 170,113 | $54.86 | $9,332,399.18 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 20:27 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 631 | $109.33 | $68,984.08 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,597 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.25 to $109.38 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 20:27 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 169,482 | $108.61 | $18,407,219.69 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,228 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.207 to $109.20 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 20:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 74,384 | $107.74 | $8,014,132.16 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,597 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:27 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 3,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002596 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,981 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right To Buy) · Derivative | 192,546 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · derivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,546 Underlying: Common stock · 192,546 shares Expires 2031-02-17 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 64,182 on February 18, 2022, 64,182 on February 18, 2023, and 64,182 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 34,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,306 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 29,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,368 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 23,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,262 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 80,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,657 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| December 23, 2020 Filed Dec 31, 2020 13:13 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 29,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-012331 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,400 Read SEC document |
| December 07, 2020 Filed Dec 11, 2020 16:34 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 3,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011834 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,417 Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 17:54 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption(Right to buy) · Derivative | 109,097 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-20-011056 · edgar.xml · derivative · entry 10 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,097 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 17:54 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption(Right to buy) · Derivative | 85,057 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001179110-20-011056 · edgar.xml · derivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,113 Underlying: Common Stock · 85,057 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 17:54 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 16,171 | $97.49 | $1,576,493.00 |
DisclosureSEC source: 0001179110-20-011056 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,642 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.39 to $97.65, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 17:54 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 177,983 | $97.06 | $17,275,296.95 |
DisclosureSEC source: 0001179110-20-011056 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,813 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.385 to $97.38, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 17:54 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 109,097 | $58.88 | $6,423,631.36 |
DisclosureSEC source: 0001179110-20-011056 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 12, 2020 17:54 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 85,057 | $54.86 | $4,666,227.02 |
DisclosureSEC source: 0001179110-20-011056 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 17:54 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 37,450 | $95.74 | $3,585,463.00 |
DisclosureSEC source: 0001179110-20-011056 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,642 Read SEC document |
| April 28, 2020 Filed May 12, 2020 17:45 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 5,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Step-son Disclosed balance after: 5,900 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| April 28, 2020 Filed May 12, 2020 17:45 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 5,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Step-daughter Disclosed balance after: 5,900 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| April 28, 2020 Filed May 12, 2020 17:45 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 10,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 17,615 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| April 28, 2020 Filed May 12, 2020 17:45 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005831 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,092 Read SEC document |
| March 25, 2020 Filed Apr 2, 2020 17:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 56,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004512 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,892 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:53 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 88,719 | $85.42 | $7,578,376.98 |
DisclosureSEC source: 0001179110-20-002854 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,842 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 18:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 3,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002138 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,561 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 229,132 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002138 · edgar.xml · derivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,132 Underlying: Common Stock · 229,132 shares Expires 2030-02-19 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 76,378 on February 20, 2021, 76,377 on February 20, 2022, and 76,377 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 29,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002138 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,236 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 23,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002138 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,129 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 39,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002138 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,525 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 108,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002138 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,416 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| December 04, 2019 Filed Dec 13, 2019 16:48 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012745 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,974 F1 · balance_after: Current balance reflects adjustment to correct administrative error in previous filings. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 16:31 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 15,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010239 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,155 Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 16:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 3,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009961 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,165 Read SEC document |
| August 02, 2019 Filed Aug 2, 2019 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 15,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009058 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,215 Read SEC document |
| May 22, 2019 Filed Aug 2, 2019 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 6,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009058 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,548 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:55 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 72,925 | $79.41 | $5,790,974.25 |
DisclosureSEC source: 0001179110-19-003079 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,923 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:24 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 179,127 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002374 · edgar.xml · derivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,127 Underlying: Common Stock · 179,127 shares Expires 2029-02-20 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 59,709 on February 21, 2020, 59,709 on February 21, 2021, and 59,709 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:24 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 23,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,812 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:24 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 39,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,207 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:24 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 42,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,098 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:24 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 59,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,449 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| January 09, 2019 Filed Feb 22, 2019 17:24 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon stock, $0.01 par value | 2,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002374 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,848 Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 16:56 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 16,850 | $88.75 | $1,495,437.50 |
DisclosureSEC source: 0001179110-18-013835 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,203 Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 17:12 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 4,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013330 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,053 Read SEC document |
| March 16, 2018 Filed Apr 13, 2018 18:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005643 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,715 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| March 16, 2018 Filed Apr 13, 2018 18:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 5,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005643 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,290 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:28 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 8,280 | $117.88 | $976,083.66 |
DisclosureSEC source: 0001179110-18-003329 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,012 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.865 to $117.901, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.